China Builds Hospital Dedicated To Heavy Ion Cancer Treatment
This article was originally published in PharmAsia News
Executive Summary
China is building a hospital in a Northwestern province it hopes to be a world magnet for heavy ion therapy for cancer patients. The head of the modern physics section of the Chinese Academy of Sciences said the Lanzhou Heavy Ion Cancer Treatment Center would be able to treat 2,000 cancer patients per year. The academy conducted clinical trials of heavy-ion treatment and reported success in eliminating most detectable tumors. It also said that in 90 percent of patients, there were no relapses after 18 months. The center is expected to cost $146 million. (Click here for more
You may also be interested in...
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.